Emcure Pharmaceuticals Announces Strong Q3FY25 with 18% Revenue Growth and 30% Profit After Tax Growth
- Revenue from operations at Rs 1,963 Cr, up 17.7% YoY
- EBITDA margins at 18.4% with EBITDA up 23.2% YoY
- PAT at 156Cr, up 30.3% YoY
- Domestic business sales at 888 Cr, up 12.0% YoY
- International business sales at 1,075 Cr, up 23.0% YoY
Bengaluru: Emcure Pharmaceuticals Ltd. (BSE:544210, NSE: EMCURE) today announced its unaudited consolidated financial results for the quarter ended December 31st, 2024.
The quarter saw strong growth led by the International businesses that grew 23% YoY. The Canadian business continues to perform well, achieving a 34% YoY growth and the Mantra subsidiary is now fully integrated. Company’s Rest of the World (RoW) market business grew a robust 40% YoY aided by strong growth in our non-ARV segment. The company continues to see traction in its key focus markets led by its differentiated product portfolio. Emcure’s Domestic business grew by over 12% to ₹ 888 Cr, led by a steady performance in the base business and aided by in-licensed products.
Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, “Emcure witnessed a strong performance in Q3. Our International business is seeing strong performance on back of our differentiated product portfolio. On the domestic side, our focus is on expanding our covered market through differentiated product launches and driving synergies from the in-licensed Sanofi portfolio. Moving forward, we aim to enhance our organic growth and margins through new product launches and operating efficiencies.”
| Rs Cr. | 3Q25 | 3Q24 | YOY% | 2Q25 | QOQ% |
| Revenue from operations | 1,963 | 1,668 | 17.7% | 2,002 | -2.0% |
| Domestic | 888 | 794 | 12.0% | 933 | -4.8% |
| International | 1,075 | 874 | 23.0% | 1,069 | 0.5% |
| Rest of the world | 365 | 260 | 40.4% | 411 | -11.3% |
| EU | 358 | 351 | 1.9% | 362 | -1.2% |
| Canada & Others | 352 | 263 | 33.8% | 296 | 18.8% |
Revenue break-up:
Contd.
Performance Summary (Consolidated)
| Rs Cr | 3Q25 | 3Q24 | YOY% | 2Q25 | QOQ% |
| Revenue from operations | 1,963 | 1,668 | 17.7% | 2,002 | -2.0% |
| Material Cost | 783 | 622 | 25.9% | 789 | -0.8% |
| Gross Profit | 1,180 | 1,046 | 12.8% | 1,213 | -2.8% |
| Gross Profit Margins | 60.1% | 62.7% | 60.6% | ||
| Employee Costs | 367 | 332 | 10.5% | 356 | 3.2% |
| Other expenses | 451 | 420 | 7.4% | 477 | -5.4% |
| EBITDA | 362 | 294 | 23.2% | 381 | -5.0% |
| EBITDA Margins | 18.4% | 17.6% | 19.0% | ||
| Other Income | 4 | 29 | 36 | ||
| Depreciation and Amortisation | 97 | 84 | 97 | ||
| Finance Costs incl. Forex loss | 39 | 61 | 46 | ||
| Exceptional Items | 0 | 7 | 0 | ||
| Profit Before Tax (PBT) | 230 | 171 | 34.5% | 273 | -15.9% |
| Tax | 74 | 51 | 72 | ||
| Profit After Tax (PAT) | 156 | 120 | 30.3% | 202 | -22.6% |
| PAT Margins | 8.0% | 7.2% | 10.1% |
